id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2020-E-1326-0008,FDA,FDA-2020-E-1326,NOTICE OF FINAL DETERMINATION,Other,Letter(s),2024-08-19T04:00:00Z,2024,8,2024-08-19T04:00:00Z,,2024-08-19T15:17:40Z,,0,0,0900006486621386
FDA-2020-E-1326-0007,FDA,FDA-2020-E-1326,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2022-08-01T04:00:00Z,2022,8,2022-08-01T04:00:00Z,,2022-08-01T15:16:38Z,,0,0,0900006485200bcf
FDA-2020-E-1326-0006,FDA,FDA-2020-E-1326,"Determination of Regulatory Review Period for Purposes of Patent
Extension; SCENESSE",Notice,Determinations,2021-11-04T04:00:00Z,2021,11,2021-11-04T04:00:00Z,2022-01-04T04:59:59Z,2021-11-09T19:37:30Z,2021-24074,0,0,0900006484e17e82
FDA-2020-E-1326-0005,FDA,FDA-2020-E-1326,Letter to U S Patent and Trademark Office,Other,Letter(s),2021-10-22T04:00:00Z,2021,10,2021-10-22T04:00:00Z,,2021-10-26T14:37:15Z,,0,0,0900006484de3ff7
FDA-2020-E-1326-0004,FDA,FDA-2020-E-1326,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2021-07-26T04:00:00Z,2021,7,2021-07-26T04:00:00Z,,2021-07-26T17:44:46Z,,0,0,0900006484c0fabf
FDA-2020-E-1326-0003,FDA,FDA-2020-E-1326,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2020-05-26T04:00:00Z,2020,5,2020-05-26T04:00:00Z,,2020-05-26T17:52:00Z,,0,0,09000064846aee7f
FDA-2020-E-1326-0001,FDA,FDA-2020-E-1326,Letter from U S Patent and Trademark Office,Other,Letter(s),2020-04-30T04:00:00Z,2020,4,2020-04-30T04:00:00Z,,2020-04-30T16:22:18Z,,0,0,0900006484522f28
FDA-2020-E-1326-0002,FDA,FDA-2020-E-1326,"Patent Term Extension Application for SCENESSE Patent No 8,334,265",Other,Application,2020-04-30T04:00:00Z,2020,4,2020-04-30T04:00:00Z,,2020-04-30T16:23:58Z,,0,0,0900006484522f29